VA/DoD CLINICAL PRACTICE GUIDELINE FOR OPIOID THERAPY FOR CHRONIC PAIN

DRAFT 3 - DO NOT DISTRIBUTE
VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain
94. Turner JA, Saunders K, Shortreed SM, et al. Chronic opioid therapy urine drug testing in primary
care: Prevalence and predictors of aberrant results. J Gen Intern Med. Dec 2014;29(12):1663-1671.
95. Squeglia LM, Jacobus J, Tapert SF. The influence of substance use on adolescent brain
development. Clin EEG Neurosci. Jan 2009;40(1):31-38.
96. Giedd JN, Blumenthal J, Jeffries NO, et al. Brain development during childhood and adolescence: A
longitudinal MRI study. Nat Neurosci. Oct 1999;2(10):861-863.
97. Lynskey MT, Heath AC, Bucholz KK, et al. Escalation of drug use in early-onset cannabis users vs cotwin
controls. JAMA. Jan 22-29 2003;289(4):427-433.
98. Grant JD, Lynskey MT, Scherrer JF, Agrawal A, Heath AC, Bucholz KK. A cotwin-control analysis of
drug use and abuse/dependence risk associated with early-onset cannabis use. Addict Behav. Jan
2010;35(1):35-41.
99. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: Treatment
agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann
Intern Med. Jun 1 2010;152(11):712-720.
100. Chen J, Lu XY, Wang WJ, et al. Impact of a clinical pharmacist-led guidance team on cancer pain
therapy in China: A prospective multicenter cohort study. J Pain Symptom Manage. Oct
2014;48(4):500-509.
101. Department of Veterans Affairs. VHA handbook 1004.01. Informed consent for clinical treatments
and procedures. 2009; http://www1.va.gov/vhapublications/ViewPublication.asp?pub_ID=2055].
Accessed January 6, 2017.
102. Helft PR, Williams JR, Bandy RJ. Opiate written behavioral agreements: A case for abandonment.
Perspectives in Biology and Medicine. 2014;57(3):415-423.
103. Fishman SM, Gallagher RM, McCarberg BH. The opioid treatment agreement: A real-world
perspective. Am J Bioeth. Nov 2010;10(11):14-15.
104. Goldberg DS, Rich BA. Few benefits, likely harms: Against universal random urine drug screening in
pain management. Pain Medicine. 2014;15(12):2000-2001.
105. Arnold RM, Han PK, Seltzer D. Opioid contracts in chronic nonmalignant pain management:
Objectives and uncertainties. Am J Med. Apr 2006;119(4):292-296.
106. Patrick SW, Fry CE, Jones TF, Buntin MB. Implementation of prescription drug monitoring
programs associated with reductions in opioid-related death rates. Health Aff (Millwood). Jul 1
2016;35(7):1324-1332.
107. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with
chronic pain: A prospective cohort study. BMC Health Serv Res. 2006;6:46.
108. McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing
application of the Bradford Hill criteria. Addiction. Jul 2016;111(7):1177-1187.
109. McAuley A, Aucott L, Matheson C. Exploring the life-saving potential of naloxone: A systematic
review and descriptive meta-analysis of take home naloxone (THN) programmes for opioid users.
Int J Drug Policy. Dec 2015;26(12):1183-1188.
110. Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing
naloxone to laypersons - United States, 2014. MMWR Morb Mortal Wkly Rep. Jun 19
2015;64(23):631-635.
111. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose
education and nasal naloxone distribution in massachusetts: Interrupted time series analysis. BMJ.
2013;346:f174.
112. Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of naloxone coprescription
for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. Aug 16
2016;165(4):245-252.
February 2017 Page 184 of 192